secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001628280-22-024362
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology announces ESMO 2022 posters showing onvansertib overcomes irinotecan resistance in RAS-mutated mCRC
--------------------------------------------------------------------------------

- Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).
- Abstract 397P: Early ≥90% decrease in KRAS MAF after one cycle predicts higher ORR and longer PFS in ongoing Phase 1b/2 trial.
- Additional findings from EAP and trial data to be released during ESMO, subject to embargo policies.
- Conference call and webcast on Sept 12, 2022 at 4:30 PM ET to discuss clinical and corporate update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/0001628280-22-024362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/crdf-20220906.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-024362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer